Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Castleman Disease

• Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
• Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
• Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
• Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
• BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
• Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
• Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
• TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
• Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
• Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease
• A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
• A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
• A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
• Dose-escalation Study of Oral CX-4945
• A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
• Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
• Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
• Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease